Italy allows the use of cannabis-based medicine
June 24th, 2013
Categories : Blog
Sativex® - a marijuana related prescription drug produces by the GW Pharmaceuticals (a medical tech business of Cambridge), was approved for use in one of the major European markets. Though for the moment it will be authorized only for the treatment of a limited number of conditions, it does mark a certain breakthrough in the attitude towards the use of cannabis as a medicine. Currently only moderate and severe Multiple Sclerosis patients can benefit from the new treatment, provided the conventional anti spasticity drugs have failed.
The boss of GW Pharma, Justin Gover, stresses that the recent approval is already the 21st of its kind, bringing the relief for patients suffering from MS. “In granting reimbursement approval for Sativex®, we appreciate the foresight of the Italian authorities in recognizing the value of a medicine that treats a particularly debilitating symptom of MS that is not adequately treated with currently available medications. (…) We now look forward to working with our partners Almirall towards commercial launch in this important market in a few months’ time.” - adds Mr Gover.
GW Pharma, that recently went through a successful initial public offering on the US stock exchange (NASDAQ) that brought the company $31,2 million, will launch the new drug in September. The company that will be responsible for the distribution in Italy – Almirall SA, that had to pay €250,000 for the privilege, is in the process of completing regulatory and price details.